Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Storz Medical AG | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.
This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores. Adverse effects and adverse events without a clear causal relationship will be documented in terms of frequency and severity. Furthermore, the progression of improvement in Alzheimer's symptoms as a result of TPS treatment is summarized in various neuropsychological scales.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with Clinical Alzheimer's syndrome treated with TPS | Patients with clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months that have planned treatment with TPS |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Registry | Diagnostic Test | Clinical data collection of patients scheduled for on-label treatment |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of (Serious) Adverse Events | Number of adverse events (without causal relationship to therapy) AE, SAE (query after the first 6-cycle block and before each booster) scaling according to NRS (1-10) for each ADE (query before each stimulation) | through study completion, an average of 1 year |
| Number of adverse device effects | Number of ADEs and (U)SADEs scaling according to NRS (1-10) for each ADE (query before each stimulation) | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| ADAS | Alzheimer's Disease Asessment Scale (ADAS) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation) | Baseline, post first 6 sessions and after 3, 6, 9 and 12 months |
| Mini Mental State Examination (MMSE) baseline and follow- up |
| Measure | Description | Time Frame |
|---|---|---|
| Numeric Rating Scale (NRS) for the main symptom | Numeric Rating Scale (NRS) for the main symptom | 12 months |
Inclusion Criteria:
i. Age = 18 to 85 ii. N>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration [AT(N)], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included.
iv. TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist
Exclusion Criteria:
i. Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol
Not provided
Not provided
AD Patients undergoing TPS
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lars Wojtecki, Prof. Dr. | Contact | +492118106756 | wojtecki@uni-duesseldorf.de |
| Name | Affiliation | Role |
|---|---|---|
| Lars Wojtecki, Prof. Dr. | Heinrich-Heine-Universität | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Ernst von Bergmann Klinikum - Klinik für Neurologie und Klinische Neuropsychologie | Recruiting | Potsdam | Brandenburg | 14467 | Germany |
Not provided
| ID | Term |
|---|---|
| D000544 | Alzheimer Disease |
| ID | Term |
|---|---|
| D003704 | Dementia |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Mini Mental State Examination (MMSE) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation) |
| Baseline, post first 6 sessions and after 3, 6, 9 and 12 months |
| BDI-II | BDI-II baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation) | Baseline, post first 6 sessions and after 3, 6, 9 and 12 months |
| Clinical Dementia Rating Sum of Boxes Score (CDR-SB) | Clinical Dementia Rating Sum of Boxes Score (CDR-SB) baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation) | Baseline, post first 6 sessions and after 3, 6, 9 and 12 months |
| Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL) | Alzheimer's Disease Cooperative Study/ Activities of Daily Living Scale (ADCS-ADL) at baseline and post 6 sessions as well as after 3, 6, 9 and 12 months (desired but not mandatory, collected within 3 days after stimulation) | Baseline, post first 6 sessions and after 3, 6, 9 and 12 months |
| Evangelische Krankenhausstiftung Oldenburg - Universitätsklinik für Neurologie | Not yet recruiting | Oldenburg | Lower Saxony | 26122 | Germany |
|
| Universitätsklinikum Bonn - Klinik für Parkinson, Schlaf- und Bewegungsstörungen | Not yet recruiting | Bonn | North Rhine-Westphalia | 53127 | Germany |
|
| Neurologische Praxis Prof. Wojtecki | Not yet recruiting | Neuss | North Rhine-Westphalia | 41460 | Germany |
|
| Hospital zum Heiligen Geist GmbH & Co KG Klinik für Neurologie und Neurorehabilitation | Withdrawn | Kempen | 47906 | Germany |
| Praxis Dr. Schwarz | Recruiting | Ulm | 89073 | Germany |
|
| D024801 |
| Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |